TITLE:
Intraperitoneal distribution of alginate microcapsules in mice
AUTHORS:
F. Dagbert, Y. J. McConnell, E. Carmona, L. Sideris, J. P. Hallé, P. Dube
KEYWORDS:
Alginate Microcapsule; Peritoneal Cavity; Peritoneal Carcinosis; Thymidine Phosphorylase; HIPEC; Capecitabine
JOURNAL NAME:
Modern Chemotherapy,
Vol.3 No.1,
January
24,
2014
ABSTRACT: Introduction: Improved drug delivery mechanisms
for the treatment of residual peritoneal cancer cells following cytoreduction
surgery are needed. Alginate microcapsules are a potentially useful mechanism
for delivery of bioengineered cells, but when injected into the peritoneum, their
distribution and properties are not well described. Methods: Aliquots of 300,
600 or 1200 microcapsules were injected into the peritoneum of 81 mice. Mice
were sacrificed at 6, 12, 18, and 48 days and laparotomy was performed to
quantify the distribution of microspheres. Results: The injections were well
tolerated for up to 48 days. No peritoneal adherence or inflammatory reaction
was noted to the microcapsules. Injection of 1200 microcapsules resulted in a
better overall persistence and widespread peritoneal distribution at up to 48
days. The volume of fluid used for injection of the microcapsules did not
affect their distribution or persistence. Conclusion: The intraperitoneal
injection of alginate microspheres allows wide and persistent distribution
throughout the abdominal cavity. The next step is to test the distribution of
microcapsules when delivered following surgery in a rodent model.